The Motley Fool

Paradigm share price tanks despite positive clinical trial update

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is down 7% to $1.95 today, despite the biotech researcher today telling the market that its first ‘investigational new drug’ (IND) application had been approved by the US healthcare regulator the FDA.

This does not mean the FDA has approved a Paradigm drug for potential commercialisation, but rather means the FDA has approved the drug’s safety data and potential use to meet “an unmet clinical need”. In other words Paradigm now has the green light or ‘seal of approval’ to conduct further trials, but there’s no guarantee these will be successful.

As the real challenge of designing successful Phase III clinical trials to meet the FDA’s approval for the commercialisation of a new drug is still ahead of it.

Paradigm flagged that it intends to meet the FDA in the future to launch other NDAs for the treatment of osteoarthritis and “the rare disease mucopolysaccharidosis”. It also plans to meet with the Australian healthcare regulator the TGA to seek provisional approval for undefined products.

At a $1.95 share price it has a market value around $375 million based on 192.2 million shares on issue. As such we can see shareholders are confident this could turn out to be a rare biotech success story. 

Other more speculative biotech businesses heavily backed include Mesoblast limited (ASX: MSB) and Next Science Ltd (ASX: NXS).

Our Top 3 Blue Chip Shares for 2019 – NOW AVAILABLE!

You’re invited! For a limited time, The Motley Fool Australia is giving away an urgent new investment report detailing our 3 TOP BLUE CHIP SHARES to own in 2019.

So if you like trustworthy, stable, high-performing companies that pay fat fully franked dividends – we’ve got you covered!

Stock #1 is a beloved old Australian company turning its attention to high-margin businesses... and rapidly returning cash to shareholders with its hefty dividend...

While Stock #2 is an online powerhouse that’s rapidly gaining market share all around the globe... poised for years (or even decades) of tremendous growth...

Even better, Stock #3 offers a whopping 6.5% grossed-up dividend! Which beats the rates on term deposits right out of the water – and offers the potential for capital gains, too.

You can discover all three shares inside our new report right now. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a LIMITED TIME ONLY!

Simply CLICK HERE FOR YOUR FREE REPORT!

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

CLICK HERE FOR YOUR FREE REPORT!